
FULC Stock Forecast & Price Target
FULC Analyst Ratings
Bulls say
Fulcrum Therapeutics Inc is positioned for significant revenue growth, with projected revenues reaching approximately $560 million by 2028, driven by robust opportunities in the sickle cell disease market due to limited current treatment options. Recent clinical data indicate promising efficacy for losmapimod and FTX-6058, with notable increases in fetal hemoglobin levels and a substantial proportion of patients achieving clinically relevant thresholds, reducing the incidence of vaso-occlusive crises. Additionally, the company's enterprise value has increased to $1.39 billion, reflecting investor confidence and the potential financial impact of its ongoing clinical programs.
Bears say
Fulcrum Therapeutics Inc faces significant challenges that could adversely impact its stock performance, primarily due to concerns regarding intellectual property protection and competitive positioning. The potential for negative developmental outcomes related to its lead candidate, pociredir, as well as the possibility of failing to achieve regulatory approval, raises substantial risks for the company's future market potential and revenue projections. Furthermore, the lower baseline hemoglobin levels observed in Cohort 4 participants suggest that the efficacy of pociredir may be diminished, complicating the company’s prospects for meeting critical clinical endpoints.
This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FULC Analyst Forecast & Price Prediction
Start investing in FULC
Order type
Buy in
Order amount
Est. shares
0 shares